Keyphrases
Escherichia Coli
65%
Japan
55%
Urinary Tract Infection
49%
Chemotherapy
44%
Antimicrobial Prophylaxis
44%
Neisseria Gonorrhoeae
39%
Antimicrobial Susceptibility
37%
Levofloxacin
31%
Prostate Cancer
31%
Antimicrobial
30%
Prostate Biopsy
30%
Extended-spectrum-lactamase
29%
Surgical Site Infection
28%
Transperineal Prostate Biopsy
27%
Minimum Inhibitory Concentration
27%
Bacteremia
26%
Male Urethritis
26%
Japanese Society
25%
Clean Intermittent Catheterization
24%
Nationwide Surveillance
24%
Peritoneal Dissemination
24%
Tumor
22%
ESBL-E. Coli
22%
Resistant Strains
20%
Cephalosporins
20%
Antimicrobial Resistance
20%
Bacterial Strains
20%
Urological Surgery
20%
Fluoroquinolone Resistance
19%
Azithromycin
18%
Radical Cystectomy
18%
Older Men
18%
Antimicrobial Susceptibility Pattern
18%
Uropathogens
16%
Carcinoma of the Penis
16%
Glans
16%
Faropenem
16%
Acute Cystitis
16%
Pediatric Patients
16%
Cystitis
16%
Bacterial Isolates
16%
Recurrent Urinary Tract Infections (rUTIs)
16%
Surveillance Program
16%
Laparoscopic Radical Prostatectomy
16%
Perioperative Infection
16%
Febrile Conditions
16%
Clinical Efficacy
16%
Urological Cancer
16%
Penicillin-binding Protein 2
16%
PenA
16%
Pharmacology, Toxicology and Pharmaceutical Science
Antiinfective Agent
100%
Urinary Tract Infection
83%
Escherichia coli
69%
Infectious Agent
41%
Neisseria gonorrhoeae
39%
Infection
37%
Urethritis
34%
Penicillinase
34%
Cystitis
33%
Quinolone Derivative
26%
Bloodstream Infection
26%
Levofloxacin
24%
Extended Spectrum Beta Lactamase Producing Escherichia Coli
23%
Minimum Inhibitory Concentration
23%
Azithromycin
18%
Chemotherapy
17%
Fropenem
16%
Cephalosporin
16%
Penicillin Binding Protein
16%
Cefixime
15%
Ceftriaxone
14%
Extended Spectrum Beta Lactamase
14%
Diabetes Mellitus
12%
Carbapenem Derivative
12%
Clinical Study
12%
Adverse Event
12%
Surgical Infection
11%
Pseudomonas aeruginosa
11%
Sitafloxacin
11%
Meropenem
11%
Bladder Cancer
11%
Chlamydia Trachomatis
9%
Amino Acid
9%
Recurrent Disease
9%
Gram Negative Bacterium
9%
Retrospective Study
8%
Proteus mirabilis
8%
Methicillin-Resistant Staphylococcus Aureus
8%
Temsirolimus
8%
Sorafenib
8%
Postoperative Infection
8%
Anaerobic Bacterium
8%
Chlamydial Urethritis
8%
Acute Pyelonephritis
8%
Kidney Metastasis
8%
Renal Cell Carcinoma
8%
Pyrrole Derivative
8%
Pyuria
8%
Candida Albicans
8%
Flucytosine
8%
Medicine and Dentistry
Antiinfective Agent
76%
Prostate Biopsy
53%
Urinary Tract Infection
41%
Infection
34%
Chemotherapy
33%
Escherichia coli
33%
Prostate Cancer
32%
Cystectomy
28%
Surgical Infection
27%
Quinolone Derivative
25%
Prostatectomy
24%
Pathogen
24%
Neoplasm
23%
Biopsy Technique
20%
Prostatitis
19%
Bloodstream Infection
19%
Transitional Cell Carcinoma
17%
Metastatic Carcinoma
17%
Adverse Event
17%
Retrospective Study
17%
Intermittent Catheterisation
16%
Transrectal Ultrasonography
16%
Carcinoma
16%
Cystitis
16%
Pediatrics Patient
16%
Phallus
16%
Urinary Tract Cancer
16%
Procalcitonin
16%
Randomized Controlled Trial
16%
Levofloxacin
16%
Penicillinase
15%
Diabetes Mellitus
13%
Prostate Specific Antigen
13%
Urologic Surgery
12%
Urinary Tract
12%
Extended Spectrum Beta Lactamase Producing Escherichia Coli
12%
Urinary Diversion
11%
Cephalosporin
11%
Febrile Neutropenia
11%
Extended Spectrum Beta Lactamase
10%
Sitafloxacin
10%
Meropenem
9%
Nephrectomy
8%
Ascending Colon
8%
Sorafenib
8%
Screening Cultures
8%
Colostomy
8%
Clear Cell Renal Cell Carcinoma
8%
Neisseria gonorrhoeae
8%
Ileus
8%